The Round-Trip Back to the Highs: A Near-Flawless FY2025 Meets a Below-Algorithm 2026 Guide and a Full Valuation — Downgrading to Hold, Taking the Gain

Results vs. Consensus

Q4 2025 & FY2025 Scorecard

Full-Year 2025 in Context

Quality of Beat/Miss

Full year: As clean as PMI has produced. Organic revenue of +6.5% (roughly +7.9% ex-Indonesia technical) sat at the high end of the 6–8% frame, organic OI grew +10.6% above the target range, and the +14.2% ex-currency EPS growth beat the company's own start-of-year expectation by 1.7 points. Adjusted OI margin crossed back above 40%. There is no soft underbelly in the FY2025 numbers.

Q4 specifically: The weakest optics of the year, and entirely by design. Q4 organic OI grew just +4.5% and Q4 organic revenue +3.7%, reflecting the phasing items management pre-announced at Q3: the ~2 billion-unit IQOS shipment reversal, the U.S. ZYN destocking, lower Q4 combustible pricing, elevated U.S. investment, and a higher Q4 tax rate. Adjusted Q4 EPS of $1.70 still grew ~10% and beat, so the "soft" quarter was soft only relative to the extraordinary first nine months.

The 2026 guide is the real news: Ex-currency EPS growth of 7.5–9.5% is the first sub-double-digit organic EPS guide in the coverage period and sits below every leg of the renewed 2026–2028 algorithm (revenue 6–8%, OI 8–10%, EPS 9–11%). Management was explicit that this is a transitory, below-trend year, but the headline +11–13% reported EPS growth is carried by a $0.27 currency tailwind, one-third of which is a non-recurring transactional swing. The quality of the 2026 growth is lower than the headline.

Segment Performance

Category Mix — FY2025

IQOS — The Watch Item, Resolved

The IQOS deceleration we flagged in October reversed exactly as management promised. HTU adjusted IMS accelerated to +12% in Q4, delivering +10.5% for the full year inside the 10–12% target, with annual adjusted IMS again adding ~15 billion units despite the EU flavor-ban headwind and intensifying competition. Europe accelerated to +10.3% IMS in Q4 (share +1.5pp to 12.0%), led by Italy's return to double-digit growth and a quarterly share above 20% for the first time. IQOS holds ~76% of the global heat-not-burn category and is now in 79 markets, with a promising Taiwan launch exiting the year at ~4% share.

"IQOS adjusted IMS growth accelerated to an outstanding plus 12% in the fourth quarter, reflecting strong momentum across the globe... this enabled us to achieve full-year growth of plus 10.5% within our target range." — Emmanuel Babeau, CFO

Assessment: This is the single most reassuring data point in the print for the bull case, and it retires the concern that carried our October conviction at only moderate. The one caveat is forward-looking: Japan HTU excise increases in April and October 2026 (discussed below) make the coming year an atypical, headwind-laden one for the category's largest market. IQOS the franchise is healthy; IQOS-in-2026 has a specific, dateable tax overhang.

ZYN — 794M Cans, and an Honest Admission

ZYN shipped 794 million U.S. cans for the year (+37%), with full-year Nielsen offtake of +25% and Q4 offtake of +23%. Management provided welcome transparency on the shipment-versus-offtake gap, estimating the underlying offtake-consistent 2025 shipment base at ~740–750 million cans, with ~25 million cans of surplus channel inventory still to normalize (most likely in Q1 2026). ZYN holds 61.5% U.S. volume share and over 67% value share, captured ~50% of category growth, and took a 10-cent-per-can price increase in December. Internationally, ZYN reached 56 markets and its ex-Nordics purchase share rose ~60% to 16%.

"ZYN is growing in the U.S., but it's not growing at our expectations. If you measure the category growth versus ZYN growth recently, this will have to be addressed... ZYN is doing okay within a three-to-six-milligram group, but clearly it's missing a higher nicotine strength." — Jacek Olczak, Group CEO

Assessment: The CEO's candor is notable and double-edged. On one hand, ZYN's leadership and offtake are strong and the December price increase signals pricing power. On the other, management openly conceded ZYN is not keeping full pace with the category because of a portfolio gap at higher nicotine strengths, which only a pending FDA authorization (ZYN Ultra) can close. That is a real, if addressable, competitive vulnerability, and it is a reason the 2026 U.S. growth contribution is guided cautiously.

Combustibles — Record Marlboro, Resilient Cash Engine

Combustibles delivered FY pricing of +7.6% (Q4 +6.8%) and gross-profit growth of +5.2% despite a 1.5% volume decline, with Marlboro reaching a record 11.0% share of the international category (ex-China) in Q4 and 25.3% total PMI cigarette share for the year. For 2026, management guides combustible pricing to ~+6% and a cigarette volume decline of ~3%, with India and Mexico excise shocks weighing on H1.

Assessment: The combustible model performed exactly to spec again: pricing well ahead of volume decline, funding the smoke-free investment and the dividend. The 2026 step-down to ~+6% pricing and a steeper ~3% volume decline (India/Mexico excise) is a modest incremental drag but well within the resilient-decline framework.

Regional & New-Segment Note

FY2025 is the last year reported under the four-geography structure. Europe crossed 50% smoke-free net revenue, joining the regions already there and taking PMI to three of four regions majority smoke-free. Effective January 1, 2026, PMI moves to three segments (International Smoke-Free, International Combustibles, U.S.), with restated 2023–2025 history promised before the end of Q1 2026. The U.S. was ~7% of net revenue and ~8% of adjusted OI in 2025.

Key Topics & Management Commentary

Overall Management Tone: Confident on the multi-year story, unusually candid on the 2026 headwinds. With CEO Jacek Olczak joining the CFO on the call, management leaned into the "best-in-class CPG growth" framing and the two-years-to-hit-three-year-targets achievement, while being transparent that 2026 is a deliberately below-algorithm year on identifiable, dateable headwinds (Japan excise, U.S. ZYN comparison, India/Mexico excise). The repeated message was "no rupture in the trend," and the evidence (IQOS +12% Q4, top-of-guide FY) supports it. The tone was that of a company managing a well-telegraphed digestion year, not one hiding a deterioration.

1. FY2025: Three-Year Targets Hit in Two

PMI delivered its three-year 2024–2026 CAGR targets for organic operating income and currency-neutral EPS in just two years, with FY2025 adjusted EPS growth of +14.2% ex-currency marking the strongest growth since 2011 (excluding the 2021 recovery). Smoke-free reached 41.5% of net revenue and ~43% of gross contribution (essentially doubled in five years), and adjusted OI margin returned above 40%.

"We have successfully achieved our three-year CAGR targets for organic OI and currency-neutral EPS in two years. This again demonstrates our ability to create sustainable value as we renew our growth targets for 2026–2028." — Jacek Olczak, Group CEO

Assessment: This is a genuinely impressive multi-year execution record and the core of why PMI has earned a premium multiple. It also, paradoxically, raises the bar: hitting the targets early pulls forward the earnings the market was waiting for, which is part of why the stock has round-tripped to the highs and why the incremental risk/reward has narrowed.

2. The 2026 Guide: A Deliberately Below-Algorithm Year

2026 organic OI growth is guided to 7–9%, below both the 2025 result (+10.6%) and the newly-renewed 8–10% target; ex-currency EPS growth of 7.5–9.5% sits below the 9–11% target. Management attributes the gap to three transitory headwinds: Japan HTU excise increases (April and October), a demanding U.S. ZYN inventory and promotion comparison (H1 2025 was under-promoted), and outsized India/Mexico combustible excise increases.

"There is no rupture in '26 versus the trend of the past years. The fundamental drivers remain exactly the same. You have this Japanese situation, which is a one-off; the high base of comparison in the U.S.; and India and Mexico with massive excise duties. But fundamentally, the powerful dynamic behind the business remains exactly the same." — Emmanuel Babeau, CFO

Assessment: We take management at its word that the headwinds are transitory and 2027 re-accelerates. But the honest reading is that 2026 is a digestion year, and the market is asked to look through it while paying ~21.6x. For a stock that has already captured the re-rating, "trust us, the algorithm resumes next year" is a Hold-quality proposition, not an Outperform-quality one.

3. Japan Excise: The Defining 2026 Headwind

Japan, IQOS's largest and most profitable market, faces two heated-tobacco excise increases in 2026 (April 1 and October), worth roughly 50–100 yen per pack or ~10–20% of current retail prices, with the greatest impact at lower price points. The tax structure is asymmetric: heated tobacco is taxed up first, cigarettes not until 2027, which pressures the category precisely where PMI leads. PMI has filed for an April price increase, and management flagged likely shipment/IMS volatility around the tax dates.

"The upcoming excise tax increases on heat-not-burn in April and October make 2026 an atypical year... once we move to '27 and beyond, more symmetry between cigarette and heat-not-burn should see IQOS resuming growth. We do not expect the underlying category growth trend to change." — Jacek Olczak, Group CEO

Assessment: This is the most concrete, dateable risk to the 2026 numbers and the single biggest reason the guide sits below algorithm. Heated-tobacco consumers have historically shown more price resilience than cigarette smokers, and the asymmetry reverses in 2027, so the thesis is intact on a multi-year view. But 2026 Japan is a genuine air-pocket for the highest-margin part of the smoke-free business, and it argues for patience rather than pressing the position at the highs.

4. ZYN's Portfolio Gap and the ZYN Ultra Catalyst

Management was refreshingly direct that ZYN is not fully keeping pace with the U.S. category because it lacks a higher-nicotine-strength offering, a gap that ZYN Ultra (a pending FDA submission in the agency's pilot program, covering higher strengths and additional flavors) is designed to close. Management said it has readiness to launch "essentially as we speak," pending FDA action it hopes could come around summer 2026, while declining to forecast the agency's timing.

"We have a readiness to launch the product essentially as we speak. It all depends how quickly we can get an answer from FDA... I think it's going to happen, summer this year. The plan is well balanced." — Jacek Olczak, Group CEO

Assessment: ZYN Ultra is the most tangible 2026 upside catalyst, and its absence from the current run-rate is a headwind embedded in the guide. If it clears the FDA in 2026, it both closes the competitive gap and adds growth the guide does not assume. The problem for the rating is that FDA timing is unforecastable, so it is optionality, not a modelable near-term driver. We would rather own that optionality after a pullback than at the highs.

5. ZYN Margin Normalization, the December Price Increase, and Ferrari

The H2 2025 normalization of U.S. ZYN promotional intensity (from the abnormally-low ~20%-on-promo of H1) is now an established base; management reiterated ZYN's gross margin remains best-in-class within PMI, above the IQOS average, and framed the mix as an enduring positive. ZYN took a 10-cent-per-can price increase in December, and PMI announced a global ZYN–Ferrari Formula 1 partnership to build premium brand equity with an adult audience.

Assessment: The margin-quality concern we raised at the October upgrade has stabilized: promotion normalized, price rose, and margins stayed best-in-class. The Ferrari partnership is a brand-equity investment (with associated cost) rather than a near-term financial driver. Net, the ZYN margin story is settled enough to no longer be a swing factor, which removes a bear point but also removes a source of upside surprise.

6. New Segment Reporting Goes Live

Effective January 1, 2026, PMI reports three segments: International Smoke-Free, International Combustibles, and U.S. Restated 2023–2025 history will be disclosed before the end of Q1 2026. For the first time, the U.S. (and therefore ZYN's economics) will be visible as a standalone segment.

Assessment: This is a structural positive we flagged at Q3, and it lands as a 2026 catalyst. Surfacing ZYN's standalone margin and growth should, on balance, support the valuation by replacing management's "best-in-class, trust us" characterization with reported numbers. It is one of the few clear positive catalysts in an otherwise digestion-flavored 2026.

7. Capital Allocation: Dividend Payout Reaches 75%, Deleveraging to ~2x

PMI's dividend payout has reached its ~75%-of-adjusted-EPS target, which management says now allows dividend growth closer to earnings growth (as demonstrated by September's 8.9% raise). The company closed 2025 at 2.5x adjusted leverage (currency-impacted) and targets close to 2.0x by end-2026, with 2026 operating cash flow guided to ~$13.5 billion. No buybacks are planned in 2026.

Assessment: Reaching the payout target and the ~2x leverage goal by end-2026 is the milestone that unlocks incremental capital-return flexibility (potentially buybacks) in 2027+. It is a reason to stay constructive on the multi-year story even while stepping aside on valuation today: the balance-sheet repair is nearly complete, and the next capital-allocation lever is coming into view.

8. State-Level Pouch Excise Risk

Asked about a reported New York proposal for a significant excise tax on nicotine pouches and the risk of other states following, management called such measures "counterproductive to the health benefit" of switching but acknowledged U.S. states act independently and the situation is fluid.

Assessment: A new, low-probability-but-watch regulatory tail for the U.S. ZYN story. State-level pouch excise taxes would raise consumer prices and could shift the promotional/competitive landscape. Not a 2026 model driver, but a reason the regulatory bear point on the U.S. is now marginally more active than it was.

Guidance & Outlook

The guide is a study in composition. On a reported basis, 2026 looks like another double-digit-EPS-growth year ($8.38–$8.53, +11–13%). Strip the $0.27 currency tailwind (one-third of which management flagged as a non-recurring transactional benefit) and the underlying growth is +7.5–9.5%, below all three legs of the algorithm PMI renewed on the same call. Management is transparent that 2026 is atypical, and the below-algorithm shape is concentrated in identifiable items: Japan HTU excise, the U.S. ZYN inventory/promo comparison, and India/Mexico combustible excise.

The Q1 2026 setup is soft by design: management guided Q1 adjusted EPS of $1.80–$1.85 (including a 14-cent FX tailwind) and described it as the softest quarter of the year, with broadly flat organic net revenue and operating income on demanding comparisons (combustible volumes down up to 5% lapping prior-year growth, the ZYN inventory normalization, and a heavier phasing of global smoke-free investment). Investors should not read a weak Q1 as a change in trajectory; it is baked into the plan.

Guidance style: Consistent with PMI's conservatism, but the message is different from the past two years. Where 2024 and 2025 were above-algorithm beat-and-raise years, 2026 is framed upfront as a below-algorithm digestion year with a recovery deferred to 2027. That reframing, delivered at a full valuation, is the crux of our downgrade.

Analyst Q&A Highlights

Why 2026 Sits Below the Renewed 2026–2028 Algorithm

The opening question sought to reconcile the below-algorithm 2026 guide with the reacceleration implied by the renewed three-year targets. Management enumerated the specific, transitory drivers and made the case that they clear by 2027.

Q: "Can you expand on the reacceleration in smoke-free volume growth compared to the 2026 growth guidance? And you called out the U.S. as a new market in the outlook."
— Matt Smith, Stifel

A: "The acceleration beyond '26 mainly comes from the implementation of tax changes in Japan. Japan has an asymmetric multi-step excise, heated tobacco taxed first, then cigarettes as of '27. So there will be some headwinds on category and IQOS growth in '26, but once we move to '27 with more symmetry, IQOS should resume growth. The second factor is the highly competitive U.S. environment and the portfolio asymmetry we expect to address with pending FDA authorizations through '26 and definitely '27."
— Jacek Olczak, Group CEO

Assessment: The reacceleration case rests on two dated events, Japan excise symmetry in 2027 and FDA authorizations (ZYN Ultra, IQOS ILUMA) landing in 2026–2027. Both are plausible and neither is in management's control. That is a perfectly reasonable multi-year thesis, but it is a "wait for 2027" thesis, which does not support paying a full multiple in early 2026.

Whether IQOS ILUMA U.S. Is in the Numbers

An analyst pressed for clarity on how much of the guide and the three-year algorithm depends on a U.S. IQOS ILUMA launch, given the long-awaited FDA authorization.

Q: "To be explicit on the 2026–2028 guidance, '26 does not include anything for ILUMA in the U.S., but there is something included for the 2027–2028 time frame. Is that fair?"
— Eric Serrano, Morgan Stanley

A: "That is broadly fair. We've made assumptions for IQOS entering the U.S. market in a planned period, but the algorithm we laid down is not heavily or materially dependent on IQOS in the U.S. IQOS is included, both the investment and some expected volumes."
— Jacek Olczak, Group CEO

Assessment: A useful de-risking of the algorithm, the three-year targets do not lean on an ILUMA U.S. launch, so a further FDA delay would not break them. But it cuts both ways: it also means the near-term guide contains ILUMA investment without ILUMA revenue, a small drag, and that the biggest U.S. optionality remains deferred and unmodelable.

Japan Excise Elasticities and the Margin Offset

A question probed the volume elasticity PMI expects from the Japan excise increases and whether incremental pricing can still drive regional margin expansion and income growth.

Q: "Could you talk about the elasticities you're expecting, with volumes I assume being pretty negatively impacted? And will the leverage on incremental pricing be enough to drive margin expansion and income growth in the region?"
— Bonnie Herzog, Goldman Sachs

A: "Consumers will start seeing the prices as of April 1. There will be some IMS/shipment distortions, consumers buying ahead or not, which will wash out for the year. The size of the excise may not immediately warrant margin expansion depending on the strategy at play, but over a bit longer period of time, with our approach to passing on prices and working on margin, we will get where we want to get."
— Jacek Olczak, Group CEO

Assessment: The non-committal answer on near-term margin is itself informative: management would not promise that Japan pricing offsets the excise-driven volume hit within 2026. It frames the recovery as "over a bit longer period," which is consistent with 2026 being a digestion year in the highest-margin market. This reinforces the below-algorithm read.

2026 Investment Intensity and the Path to a Beat

A question asked management to frame the key drivers that could allow PMI to deliver or beat the 2026 guide, and how much the plan assumes in incremental investment spend versus 2025.

Q: "Could you frame the key growth drivers that will allow you to deliver on your top and bottom-line guidance and possibly beat it? And how much of an increase does your guidance assume in planned investment spend this year versus last?"
— Bonnie Herzog, Goldman Sachs

A: "There is no rupture in '26 versus the trend. The fundamental drivers remain exactly the same, a powerful smoke-free portfolio, positive mix on margin, and a resilient combustible model. You have the Japanese situation, which is a one-off, and the high U.S. base of comparison. The '26 objective is not very far from the mid-term CAGR; we have a couple of special events to overcome."
— Emmanuel Babeau, CFO

Assessment: Management is consistent and credible that the underlying engine is unchanged. But "a couple of special events to overcome" is precisely why 2026 EPS growth is guided below trend, and why the investment case for the next twelve months is a hold rather than a press. The drivers of a beat (FDA approvals, Japan pricing sticking) are the same unforecastable catalysts noted elsewhere.

The Absence of ZYN Promotions and the Portfolio Gap

An analyst noted a conspicuous absence of ZYN promotions in recent months and asked whether it reflected a deliberate shift ahead of a ZYN Ultra launch, tying it to the higher-strength portfolio gap.

Q: "We've observed a notable absence of ZYN promotions over the last two months in the U.S. Is this a deliberate shift as you await ZYN Ultra, or a shift in how aggressively you want to drive trial versus capturing the 50% category growth?"
— Faham Baig, UBS

A: "There were a couple of schemes in Q3 and Q4 we didn't repeat, that was our decision. But I wouldn't conclude too much from a short period. Long-term success rests on three aspects: brand building, a portfolio meeting current trends, and price. ZYN is doing okay within the three-to-six-milligram group, but clearly it's missing a higher nicotine strength, maybe nine, which we'll have to address, and here we need to work with FDA."
— Jacek Olczak, Group CEO

Assessment: The most candid competitive admission on the call. ZYN's promotional cadence will be lumpy, and its full-category participation genuinely depends on FDA clearing a higher-strength product. It confirms that the U.S. is both PMI's biggest opportunity and, in 2026, a source of comparison and portfolio-gap drag, which is exactly why we are content to wait.

The 2026 Currency Tailwind and Its Composition

A question asked why the 2026 currency guidance came in well above Street estimates and what drove it.

Q: "The currency guidance for the year was significantly better than the Street estimates. Could you share the key drivers?"
— Faham Baig, UBS

A: "The reason is that we are going to benefit from some significant negative transactional impact in 2025 which is not going to repeat. Of the 27-cent guidance, about two-thirds is translation and around one-third comes from a transactional non-repeat. That is probably what the Street doesn't have. On the yen, we still enjoy a slightly better rate than spot, but we expect another negative impact from the Japanese yen in '26."
— Emmanuel Babeau, CFO

Assessment: This decomposes the headline EPS growth. Roughly a third of the $0.27 tailwind is a one-time reversal of 2025's transactional losses, not a durable rate benefit, which is why we anchor on the +7.5–9.5% ex-currency growth as the true underlying pace. It is a reminder that PMI's reported EPS carries meaningful, and not always favorable, FX noise.

What They're NOT Saying

1. A quantified Japan 2026 volume/IMS impact. Management flagged the excise headwind and likely shipment volatility but would not size the Japan volume or margin hit, deferring to "it will wash out for the year" and a longer-term pricing recovery. The magnitude of the biggest 2026 headwind is left unquantified.
2. A firm ZYN Ultra or IQOS ILUMA FDA date. Management "won't do any fortune-telling" on FDA timing, hoping for ZYN Ultra "around summer" but committing to nothing, and confirming the three-year algorithm does not lean on ILUMA U.S. The two biggest U.S. catalysts remain unmodelable.
3. Whether 2026 organic OI growth of 7–9% is truly the trough. Management asserts a 2027 return to algorithm but provided no bridge or interim milestones, leaving investors to take the reacceleration on faith.
4. The standalone U.S./ZYN segment margin. Despite the January 2026 segment change, no preview of the restated U.S. segment economics was offered; the "best-in-class margin" characterization remains a description rather than a number until the Q1 restatement.
5. Any 2026 buyback. With leverage reaching ~2x and the payout target hit, management pointedly reiterated no buybacks in 2026, deferring incremental capital return to 2027+ without specifics.

Market Reaction

• Pre-print setup (Feb 5 close): $182.00, up ~13.5% year-to-date just five weeks into 2026 and ~17.3% over the trailing 30 days, sitting within a fraction of the 52-week closing high of $184.95. The stock had rallied ~20% off the October low (~$152), so it entered the FY print priced for good news.
• Reaction session (Feb 6): Gapped down ~1.2% at the open ($179.83), traded a $178.00–$186.55 range, and closed at $182.81, up 0.4% (+$0.81).
• Relative move: The S&P 500 rose 2.0% on the session, so PM effectively lagged the tape by ~1.6 points, a relative underperformance on a strong FY report.
• Volume: 8.6M shares versus a 5.3M 30-day average (1.6x), an orderly session, neither a capitulation nor a rip.

The muted, market-lagging reaction to a top-of-guide FY print is the most important signal in the tape, and it is the one our downgrade leans on. When a stock cannot rally on excellent results and a three-year-targets-in-two achievement, it is because the results were expected and the price already reflects them. Layered on top, the 2026 guide sits below the company's own renewed algorithm, giving the marginal buyer a reason to wait for a better entry.

None of this is bearish on the business. It is a statement about risk/reward at $183. The stock has completed the ~20% move we upgraded to capture in October, round-tripped to its highs, and now discounts a digestion year. That is the textbook profile of a position to harvest, not to press.

Street Perspective

Debate: Is 2026's Below-Algorithm Guide Transitory or the Start of Maturation?

Bull view: The 2026 shortfall is fully explained by dateable, one-off items, Japan HTU excise (which reverses toward symmetry in 2027), a U.S. ZYN inventory/promo comparison, and India/Mexico combustible excise. The underlying smoke-free engine is unchanged (IQOS +12% Q4), FDA catalysts (ZYN Ultra, ILUMA) offer un-modeled upside, and 2027 resumes the 9–11% EPS algorithm.

Bear view: Guiding below algorithm the first year after renewing the algorithm is a yellow flag. Japan, the profit engine, faces a real tax headwind; ZYN is openly "not growing to expectations" on a portfolio gap; and the reported growth leans on a currency tailwind. If any headwind proves stickier than "transitory," the premium multiple is exposed.

Our take: Bull on the multi-year business, neutral on 2026. We believe management that the headwinds are largely transitory, but "believe us, it re-accelerates in 2027" is not a proposition worth paying ~21.6x for today. The base case is a year of digestion at a full valuation, which is the definition of a Hold.

Debate: Has the Valuation Round-Trip Removed the Edge?

Bull view: At ~21.6x with a ~3.2% growing yield, a completed balance-sheet repair (payout at 75%, leverage to ~2x), and 2027 catalysts, PMI is still a best-in-class CPG compounder worth owning through a soft year. The multiple has held despite the deceleration, evidence of the market's conviction in the multi-year story.

Bear view: The stock has round-tripped from ~$152 to ~$183 in under four months and sits at its highs on a year guided below trend. There is no valuation cushion, ESG constraints cap the buyer base, and a below-algorithm year at a peak multiple is where drawdowns start. The +0.4% reaction to a great print says the upside is already spent.

Our take: Bear on the near-term edge. This is precisely the mirror image of our October call: then the stock had de-rated to ~20x into an accelerating franchise (buy); now it has re-rated to ~21.6x into a decelerating guide (step aside). The business is the same and excellent; the price has moved against the buyer.

Debate: Is ZYN's Portfolio Gap a Real Vulnerability?

Bull view: ZYN still leads with 61.5% volume and 67% value share, took a December price increase, and the gap is a single pending FDA product (ZYN Ultra) away from closing, with launch readiness already in place. The Ferrari partnership and international expansion add durable equity.

Bear view: Management openly conceded ZYN is not keeping pace with a 40%-growing category because it lacks higher-strength products, ceding share of category growth to competitors while it waits on the FDA. In the fastest-growing U.S. nicotine category, a portfolio gap at the point of maximum growth is a costly place to be stuck.

Our take: A real but addressable vulnerability. ZYN Ultra clearing the FDA in 2026 would flip it to a catalyst; continued delay lets competitors entrench in the higher-strength segment. It is a genuine two-sided risk that adds to the case for waiting rather than pressing.

Model & Valuation Framework

Valuation: At $182.81 and a 2026 adjusted-EPS midpoint of ~$8.455, PMI trades at ~21.6x forward earnings with a ~3.2% dividend yield, versus ~20.2x at our October upgrade. The stock has re-rated roughly a turn and a half while its forward EPS growth decelerated from +14% (2025) to +7.5–9.5% ex-currency (2026 guide). On a forward 2027 EPS of ~$9.35 (assuming the algorithm resumes), PM trades at ~19.5x, which is where the multi-year value re-emerges, but that is a 2027 story.

12-month price target framework: Base case ~$185–195 (roughly 22x our ~$8.55 blended NTM EPS, the current multiple held), implying a low-single-digit price return plus the ~3.2% yield, a total return roughly in line with our S&P 500 expectation and consistent with a Hold. Bull case ~$210–220 (24–25x if ZYN Ultra and/or ILUMA clear the FDA in 2026 and the market prices the 2027 re-acceleration early). Bear case ~$150–160 (17–18x if Japan excise elasticity disappoints, ZYN's portfolio gap costs share, or the market de-rates a below-algorithm year at peak multiples). The up-to-down skew from $183 is now roughly balanced-to-unfavorable (~+18% bull / ~-16% bear), the inverse of October, which supports the downgrade to Hold.

Thesis Scorecard Post-Earnings

We grade the standing thesis carried since our October upgrade. The business pillars remain intact to strengthened; what changed is the valuation (re-rated back to the highs) and the near-term growth cadence (2026 guided below algorithm), which together drive the rating action.

Overall: The thesis is fundamentally unchanged and, on the business, arguably stronger (IQOS resolved, targets hit early). But two of the swing factors moved against the near-term risk/reward: valuation re-rated back to the highs (Bear-1 re-emerged) and the 2026 growth cadence is guided below algorithm (Bear-3 re-framed and materializing). Regulatory (Bear-4) is incrementally more active on the Japan and U.S. excise fronts.

Action: Downgrade to Hold from Outperform. This is a valuation and cycle-position call, the mirror image of the October upgrade: we bought a de-rated franchise into an acceleration; we now step aside from a re-rated one into a guided deceleration. It is emphatically not a thesis break, FY2025 was excellent and the multi-year story is intact. Re-upgrade triggers: a pullback that resets the multiple toward ~18–19x, OR clear evidence that 2026 is the trough (Japan excise absorbed, a ZYN Ultra or IQOS ILUMA FDA approval, the U.S. segment restatement confirming best-in-class ZYN economics). We would consider Underperform only if a "transitory" headwind proves structural, which is not the base case.

Bottom Line: Great Year, Full Price, Take the Gain

FY2025 was one of the best years in Philip Morris's modern history: adjusted EPS at the top of guide with the fastest growth since 2011, smoke-free at 41.5% of revenue, three-year CAGR targets delivered in two, and the IQOS deceleration that tempered our October conviction fully reversed with a +12% Q4. On the fundamentals, this is a company executing at a very high level, and nothing in this print changes the multi-year thesis.

What changed is the setup. We upgraded in October at ~$152 and ~20x specifically because a de-rated entry had lined up with a confirmed ZYN inflection. The stock proceeded to do exactly what we hoped, rallying ~20% back to its all-time high, and in the process it spent the edge. At ~$183 and ~21.6x, PMI now trades at a full multiple into a 2026 that management itself guides below its renewed algorithm, on a Japan excise headwind and a U.S. ZYN comparison that will make the reported growth lean on currency. The market's +0.4% reaction to a top-of-guide FY print, on a day it rose 2.0%, confirms the good news is in the price.

We are downgrading to Hold and taking the gain. This is a discipline call, not a bearish one: we owned the transformation into its acceleration and we harvest it at the highs into a digestion year. The path back to Outperform is clear and we will be watching for it, a valuation reset that restores the cushion, or hard evidence that 2026 is the trough and the 2027 re-acceleration is in hand. Until one of those arrives, the risk/reward at the highs is balanced-to-unfavorable, and the right posture is patience.